High risk basal cell carcinoma, response to combined HeberFeron treatment and surface radiotherapy. Presentation of a case
Keywords:
basal cell carcinoma, HeberFeron, surface radiotherapy, combined treatmentAbstract
Introduction: basal cell carcinoma is a malignant tumor of cutaneous location and is the most frequent in humans, especially in the white race. When it appears in the periocular region it is considered to be of high risk due to the possibility of invasion into adjacent and underlying structures.Case presentation: male patient, skin phototype II, who came to the clinic because of the presence of a tumor lesion of 5X2.5cm in diameter, located in the left temple, involving the external angle of the eye. Clinical and histological diagnosis was made and treatment with HeberFeron was decided due to the location and size of the lesion. A first cycle of treatment was performed and a partial response was obtained with a reduction of the lesion to 2x2cm, and then a second cycle of treatment was decided. It was maintained as a stable disease, so treatment with superficial radiotherapy was indicated; it presented complete disease response, clinical and dermatoscopic.
Conclusion: HeberFeron therapy was effective in reducing the lesion and, combined with superficial radiotherapy, achieved a complete clinical response and excellent aesthetic results.
Downloads
References
1. Carucci JA, LeffellDJ, Pettersen JS. Carcinoma Basocelular. En: Dermatología en medicina General. Fitzpatrick. 8va ed. España: Editorial Médica Panamericana; 2014.p. 1293-1301.
2. Arena Guzmán R. Dermatología, atlas, diagnóstico y tratamiento.5ta ed. México: McGraw-Hill INTERAMERICANA EDITORES, S.A; 2013 .p. 745-753.
3. Rocken M. Schaller M. Sattler E. Burgdorf W. Dermatología texto y atlas. España: Editorial Medica Panamericana; 2013. p. 216-221.
4. Fitzpatrick´s, Wolff K, Richard A. Atlas en color y sinopsis de dermatología clínica. 7ma ed. Madrid, España: Mc Graw Hill Interamericana; 2013. p. 240-46.
5. Darias Domínguez C, Garrido Celis J. Carcinoma basocelular. Un reto actual para el dermatólogo. Rev Med Electrón [Internet]. 2018 Ene-Feb [citado 18/03/2019];40(1):172-182. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242018000100017&lng=es
6. Andrews Odom RB, James WD, Berger TG. Nevus, neoplasias y quistes epidérmicos. En: Dermatología Clínica. Madrid, España: Mc Graw Hill Interamericana; 2014. p. 820-29.
7. Sociedad Argentina de Dermatología. Consenso sobre carcinoma basocelular. Carcinoma espinocelular. Guía de recomendaciones. Argentina: SAD; 2005. p. 7-18. Disponible en: http://www.sad.org.ar/wp-content/uploads/2016/04/basoespino.pdf
8. Jiménez Barbán Y, Vega Pupo C, Vila Pinillo D, Fernández Ychaso G, Arias Núñez V, Bello Rivero I. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cubana Oftalmol [Internet]. 2014 Jul-Sep [citado 18 Mar 2019];27(3):482-489. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300014&lng=es
9. CECMED. Resumen de las características del producto. HeberFeron® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec) [Internet]. La Habana: Centro para el Control Estatal de Medicamentos; 2017 [citado 18/03/2019]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_heberferon_0.pdf
10. American Cáncer Society. Radioterapia para los cánceres de piel de células basales y de células escamosas. Atlanta: American Cáncer Society; 2016 [actualizado 17 May 2016; citado 19 Mar 2019]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-piel-de-celulas-basales-y-escamosas/tratamiento/radioterapia.html
11. Instituto Nacional del Cáncer. Tratamiento del carcinoma de células basales [Internet]. USA: Instituto Nacional del Cáncer; 2019 [actualizado 28 Feb 2019; citado 19 Mar 2019]. Disponible en: https://www.cancer.gov/espanol/tipos/piel/pro/tratamiento-piel-pdq
12. Eva Garagorri E, Luis Valdivia L, Bruno Ciriani B, José Chang J. Evaluación de la radioterapia superficial en el tratamiento del carcinoma basocelular en el servicio de dermatología del Hospital Central de la FAP. Dermatol Peru [Internet]. 2002 [citado 14/03/2019];12(3):190-97. Disponible en: http://sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v12_n3/evaluacion.htm
13. Rojas Rondón I, Duncan Roberts Y, Gómez Cabrera CG, Ramírez García LK, Vigoa Aranguren L, Hernández Rodríguez R, et al. Administración del HeberFeron en el carcinoma basocelular palpebral a propósito de 2 casos. Bionatura [Internet]. 2016 [citado 14/03/2019];1(2):71-4. Disponible en: http://revistabionatura.com/heberferon.html
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms:
- Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
- Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
- Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
15 junio 2025
